DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 168.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 272,622 shares of the medical device company's stock after purchasing an additional 171,150 shares during the quarter. DexCom accounts for 1.1% of Motley Fool Asset Management LLC's holdings, making the stock its 22nd largest holding. Motley Fool Asset Management LLC owned 0.07% of DexCom worth $17,993,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Blue Whale Capital LLP increased its holdings in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock worth $15,821,000 after purchasing an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC increased its stake in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after buying an additional 11,075 shares during the period. Brooktree Capital Management purchased a new stake in shares of DexCom during the third quarter worth approximately $683,000. National Pension Service increased its stake in shares of DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company's stock worth $63,671,000 after buying an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in shares of DexCom during the third quarter worth approximately $650,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is currently owned by corporate insiders.

DexCom Trading Up 0.1 %

Shares of NASDAQ DXCM traded up $0.10 during midday trading on Wednesday, hitting $81.01. The stock had a trading volume of 3,049,587 shares, compared to its average volume of 3,909,582. The company has a market capitalization of $31.64 billion, a price-to-earnings ratio of 48.45, a PEG ratio of 2.43 and a beta of 1.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a fifty day moving average price of $71.83 and a 200 day moving average price of $86.83.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Wells Fargo & Company boosted their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. boosted their target price on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, October 25th. Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Finally, Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.